-

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Believes Removing All Incumbent Directors Will Position Pasithea to Enhance Corporate Governance, Improve Capital Allocation and Deliver Long Term Value

Urges Stockholders to Vote for ALL Proposals on the WHITE Proxy Card at Pasithea’s November 29th Special Meeting

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest external stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement in connection with its efforts to remove the Company’s Board of Directors (the “Board”) at the upcoming Special Meeting of Stockholders (the “Special Meeting”) on Tuesday, November 29, 2022:

“Our singular goal in this campaign has been to help put Pasithea back on the path to create value for stockholders. We are deeply disappointed that Pasithea has scheduled the Special Meeting to occur with just a few days of notice and over a holiday period. This is a stunning disregard for stockholder rights, and it is another in a long line of actions—including multiple dilutive acquisitions—taken by the incumbent Board that are calculated to disenfranchise stockholders. We strongly believe that it is time for stockholders to take back their Company and vote to remove all of Pasithea’s sitting directors.

We urge our fellow stockholders to vote to improve Pasithea at the Special Meeting by voting FOR all matters on the WHITE proxy card.”

***

VOTE THE WHITE PROXY CARD TODAY

If you have any questions on how to vote your shares on the WHITE proxy card, please contact InvestorCom LLC by email at info@investor-com.com or by telephone at 203-972-9300.

***

Contacts

For Investors:
Concord Investment Partners Ltd.
David Delaney, 416-951-9214
ddelaney@concordinvestmentpartners.com

InvestorCom LLC
John Grau, 203-972-9300
info@investor-com.com

For Media:
Longacre Square Partners
Charlotte Kiaie / Aaron Rabinovich, 646-386-0091
ckiaie@longacresquare.com / arabinovich@longacresquare.com

CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC

NASDAQ:KTTA

Release Versions

Contacts

For Investors:
Concord Investment Partners Ltd.
David Delaney, 416-951-9214
ddelaney@concordinvestmentpartners.com

InvestorCom LLC
John Grau, 203-972-9300
info@investor-com.com

For Media:
Longacre Square Partners
Charlotte Kiaie / Aaron Rabinovich, 646-386-0091
ckiaie@longacresquare.com / arabinovich@longacresquare.com

More News From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC

Camac Partners Calls on TuSimple to Take Long Overdue Step of Monetizing Remaining Assets and Returning Capital to Shareholders

NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (together with its affiliates, “Camac”), a 5.6% shareholder of TuSimple Holdings Inc. (OTCMKTS: TSPH) (“TuSimple” or the “Company”), today released a letter it recently sent to the Company’s Board of Directors (the “Board”). *** May 30, 2024 TuSimple Holdings Inc. Attn: The Board of Directors Dear TuSimple Board of Directors, We are a major independent shareholder of TuSimple, owning approximately 5.6% of the Company. In our view, maintaining the C...

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest external stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement recommending stockholders vote on the WHITE proxy card to remove the Company’s Board of Directors (the “Board”) at the upcoming Special M...

Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement regarding the Company's recently announced dilutive acquisition of AlloMek Therapeutics, LLC (“AlloMek”). As a reminder, the Investor Group has su...
Back to Newsroom